Kumru Hatice, Santamaria Joan, Valldeoriola Francesc, Marti Maria J, Tolosa Eduardo
Neurology Service, Hospital Clínic de Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer , Universitat de Barcelona, Barcelona, Spain.
Mov Disord. 2006 Nov;21(11):1972-4. doi: 10.1002/mds.21086.
Body weight changes occur during the clinical course of Parkinson's disease (PD) and with surgical treatment, but the effect of dopaminergic treatment on weight is unknown. Body mass index (BMI), Hamilton depression scale score (HDS), and Unified Parkinson's Disease Rating Scale III (UPRS-III) were measured before and 3 months after starting pramipexole in 28 PD patients. Pramipexole produced a significant weight increase, as well as motor and mood improvement (P <0.001). HDS and BMI changes were mildly related (P = 0.05). A direct effect of pramipexole on limbic D(3) receptors involved in the control of feeding may be responsible for weight gain in PD.
帕金森病（PD）临床病程中以及手术治疗期间会出现体重变化，但多巴胺能治疗对体重的影响尚不清楚。对28例PD患者在开始服用普拉克索前及服药3个月后测量了体重指数（BMI）、汉密尔顿抑郁量表评分（HDS）和统一帕金森病评定量表III（UPRS-III）。普拉克索使体重显著增加，同时运动和情绪也得到改善（P<0.001）。HDS和BMI变化呈轻度相关（P = 0.05）。普拉克索对参与进食控制的边缘系统D(3)受体的直接作用可能是PD患者体重增加的原因。
